Literature DB >> 16722797

Modulation of P-glycoprotein-mediated efflux by prodrug derivatization: an approach involving peptide transporter-mediated influx across rabbit cornea.

Suresh Katragadda1, Ravi S Talluri, Ashim K Mitra.   

Abstract

The aim of this study was to investigate the modulation of efflux mechanisms using transporter- targeted prodrug derivatization of a model P-gp substrate, quinidine. The L-valine, L-valine-valine esters of quinidine, val-quinidine (VQ), and val-val-quinidine (VVQ) were synthesized in our laboratory, respectively. [(14)C] erythromycin was chosen to delineate the affinity of quinidine (Q) toward P-gp. [(3)H] glycylsarcosine (GS, or glysar) was chosen as a model peptide transporter (PEPT) substrate. Uptake studies were performed on rPCEC (rabbit primary corneal epithelial culture) using 12-well plates. Transport studies were conducted with isolated rabbit corneas at 34 degrees C. Efflux of [(14)C] erythromycin was significantly increased in the presence of quinidine, whereas it was unaltered in the presence of VQ and VVQ. VVQ was more stable, both in buffers and tissue homogenate. Transport of VQ and VVQ was inhibited with GS, and their permeability values were 1.5 and 3 times higher than the permeability of quinidine, respectively. Results from this study clearly indicate that prodrug derivatization of quinidine can modulate P-gp-mediated efflux. These prodrugs have a reduced or diminished affinity toward P-gp and were further recognized by the peptide transporter- mediated process. Enhanced permeabilities of the prodrugs indicate that drug derivatization can be a viable strategy for overcoming P-gp-mediated efflux.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16722797     DOI: 10.1089/jop.2006.22.110

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  18 in total

Review 1.  Ocular drug delivery.

Authors:  Ripal Gaudana; Hari Krishna Ananthula; Ashwin Parenky; Ashim K Mitra
Journal:  AAPS J       Date:  2010-05-01       Impact factor: 4.009

Review 2.  Prodrug strategies in ocular drug delivery.

Authors:  Megha Barot; Mahuya Bagui; Mitan R Gokulgandhi; Ashim K Mitra
Journal:  Med Chem       Date:  2012-07       Impact factor: 2.745

Review 3.  Phase I and phase II ocular metabolic activities and the role of metabolism in ophthalmic prodrug and codrug design and delivery.

Authors:  Abeer M Al-Ghananeem; Peter A Crooks
Journal:  Molecules       Date:  2007-03-08       Impact factor: 4.411

Review 4.  Novel strategies for anterior segment ocular drug delivery.

Authors:  Kishore Cholkar; Sulabh P Patel; Aswani Dutt Vadlapudi; Ashim K Mitra
Journal:  J Ocul Pharmacol Ther       Date:  2012-12-05       Impact factor: 2.671

Review 5.  A comprehensive insight on ocular pharmacokinetics.

Authors:  Vibhuti Agrahari; Abhirup Mandal; Vivek Agrahari; Hoang M Trinh; Mary Joseph; Animikh Ray; Hicheme Hadji; Ranjana Mitra; Dhananjay Pal; Ashim K Mitra
Journal:  Drug Deliv Transl Res       Date:  2016-12       Impact factor: 4.617

6.  Interaction of ocular hypotensive agents (PGF2 alpha analogs-bimatoprost, latanoprost, and travoprost) with MDR efflux pumps on the rabbit cornea.

Authors:  Sudharshan Hariharan; Mukul Minocha; Gyan P Mishra; Dhananjay Pal; Rohit Krishna; Ashim K Mitra
Journal:  J Ocul Pharmacol Ther       Date:  2009-12       Impact factor: 2.671

7.  Molecular expression and functional activity of efflux and influx transporters in hypoxia induced retinal pigment epithelial cells.

Authors:  Ramya Krishna Vadlapatla; Aswani Dutt Vadlapudi; V K Chaithanya Ponnaluri; Dhananjay Pal; Mridul Mukherji; Ashim K Mitra
Journal:  Int J Pharm       Date:  2013-07-01       Impact factor: 5.875

8.  Ocular sustained release nanoparticles containing stereoisomeric dipeptide prodrugs of acyclovir.

Authors:  Jwala Jwala; Sai H S Boddu; Sujay Shah; Suman Sirimulla; Dhananjay Pal; Ashim K Mitra
Journal:  J Ocul Pharmacol Ther       Date:  2011-04       Impact factor: 2.671

9.  Peptide prodrugs: improved oral absorption of lopinavir, a HIV protease inhibitor.

Authors:  Sheetal Agarwal; S H S Boddu; Ritesh Jain; Swapan Samanta; Dhananjay Pal; Ashim K Mitra
Journal:  Int J Pharm       Date:  2008-03-28       Impact factor: 5.875

Review 10.  Advances in the use of prodrugs for drug delivery to the eye.

Authors:  Pranjal Taskar; Akshaya Tatke; Soumyajit Majumdar
Journal:  Expert Opin Drug Deliv       Date:  2016-07-21       Impact factor: 6.648

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.